Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation.
Hank K NgBritny G RogalaSteven AdesJoanna R SchwartzTakamaru AshikagaPamela VacekChris E HolmesPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
DOACs had fewer DDIs than warfarin, although interaction severity differed between anticoagulants. Some anticoagulant-drug interactions were associated with bleeding or VTE. Although not powered for analysis, DDI severity did not affect bleeding rates and inversely correlated with VTE risk.